# Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

> **NCT05628740** · PHASE1 · COMPLETED · sponsor: **Nocion Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Refractory Chronic Cough

## Interventions

- **DRUG:** 3 mg NOC-100 (via nebulizer)
- **DRUG:** 1 mg NOC-110 (via DPI) [1x 1 mg capsule]
- **DRUG:** 3 mg NOC-110 (via DPI)
- **DRUG:** Placebo (via DPI)
- **DRUG:** 6 mg NOC-110 (via DPI)
- **DRUG:** Placebo (via DPI) [2x Placebo capsules]

## Key facts

- **NCT ID:** NCT05628740
- **Lead sponsor:** Nocion Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-07
- **Primary completion:** 2022-10-25
- **Final completion:** 2022-10-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05628740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05628740, "Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05628740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*